NanoViricides is trading 5% up at $1.47 after investors continued reacting to the company’s September 15 announcement that its Phase II NV-387 oral-gummy Ebola trial is scheduled to start the following week in the Democratic Republic of Congo.
- The trial targets an expanding Ebola outbreak and follows regulatory approval and registration of the study.
- Broader biotech strength, with XBI up 2.55%, is providing additional support.